Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue British Journal of Pharmacology Année : 2017

Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies

Xavier Ligneau
Rashmi Shah
Isabelle Berrebi-Bertrand
  • Fonction : Auteur
Gary Mirams
Philippe Robert
  • Fonction : Auteur
Laurent Landais
  • Fonction : Auteur
Jeanne-Marie Lecomte
  • Fonction : Auteur
Jean-Charles Schwartz
  • Fonction : Auteur

Résumé

Background and Purpose: We evaluated the concordance of results from two sets of nonclinical cardiovascular safety studies on pitolisant. Experimental Approach: Nonclinical studies envisaged both in the International Conference on Harmonization (ICH) S7B guideline and Comprehensive in vitro Pro-arrhythmia Assay (CiPA) initiative were undertaken. The CiPA initiative included in vitro ion channels, stem cell-derived human ventricular myocytes, and in silico modelling to simulate human ventricular electrophysiology. ICH S7B-recommended assays included in vitro hERG (KV11.1) channels, in vivo dog studies with follow-up investigations in rabbit Purkinje fibres and the in vivo Carlsson rabbit pro-arrhythmia model. Key Results: Both sets of nonclinical data consistently excluded pitolisant from having clinically relevant QT-liability or pro-arrhythmic potential. CiPA studies revealed pitolisant to have modest calcium channel blocking and late INa reducing activities at high concentrations, which resulted in pitolisant reducing dofetilide-induced early after-depolarizations (EADs) in the ICH S7B studies. Studies in stem cell-derived human cardiomyocytes with dofetilide or E-4031 given alone and in combination with pitolisant confirmed these properties. In silico modelling confirmed that the ion channel effects measured are consistent with results from both the stem cell-derived cardiomyocytes and rabbit Purkinje fibres and categorized pitolisant as a drug with low torsadogenic potential. Results from the two sets of nonclinical studies correlated well with those from two clinical QT studies. Conclusions and Implications: Our findings support the CiPA initiative but suggest that sponsors should consider investigating drug effects on EADs and the use of pro-arrhythmia models when the results from CiPA studies are ambiguous.
Fichier principal
Vignette du fichier
BPH-174-4449.pdf (1.35 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03715804 , version 1 (13-12-2023)

Identifiants

Citer

Xavier Ligneau, Rashmi Shah, Isabelle Berrebi-Bertrand, Gary Mirams, Philippe Robert, et al.. Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies. British Journal of Pharmacology, 2017, 174 (23), pp.4449-4463. ⟨10.1111/bph.14047⟩. ⟨hal-03715804⟩
35 Consultations
9 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More